Drug intelligence / Profile preview

D086

Development stage: Phase 3
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D086 is a pharmaceutical drug currently under investigation by Chong Kun Dang Pharmaceutical. It is being evaluated in clinical trials, including a Phase 3 study for the treatment of primary hypercholesterolemia. The drug is administered orally, typically once daily. It has also been studied in various Phase 1 pharmacokinetic and drug-drug interaction trials, often in combination with other compounds like CKD-330 and D337, to assess its safety and how it interacts with other medications.

Targets

AGTR1 (Angiotensin II Type-1 receptor)CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on D086.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D086.

Explore the full profile